On June 7, the Food & Drug Administration approved Aduhelm (aducanumab) to treat Alzheimer's patients, making it the first new drug approval for a disease impacting more t.... Read More
The Alzheimer's Association is pleased with the announcement today that the Food and Drug Administration (FDA) has revised the prescribing label for Aduhelmâ„¢ (aducanumab). Con.... Read More
Boston-based biotech company Biogen had pre-clinical research and Phase 1b results for aducanumab, its investigational antibody treatment for early Alzheimer's disease, publis.... Read More